[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016007016A8 - composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica Download PDF

Info

Publication number
BR112016007016A8
BR112016007016A8 BR112016007016A BR112016007016A BR112016007016A8 BR 112016007016 A8 BR112016007016 A8 BR 112016007016A8 BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A8 BR112016007016 A8 BR 112016007016A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
dementia
Prior art date
Application number
BR112016007016A
Other languages
English (en)
Other versions
BR112016007016A2 (pt
Inventor
Khan Afzal
James BRAUNTON Alan
Payne Andrew
Edward Kitulagoda James
Luis Castro Pineiro Jose
Michelle Birch Louise
Soejima Motohiro
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112016007016A2 publication Critical patent/BR112016007016A2/pt
Publication of BR112016007016A8 publication Critical patent/BR112016007016A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de 4-azaindol que são moduladores do receptor muscarínico de acetilcolina (machr) m1 e que podem ser eficazes para a prevenção ou modificação de doença ou tratamento sintomático de déficits cognitivos associados com distúrbios neurológicos, tais como demência do tipo alzheimer (ad) ou demência com corpos de lewy (dcl) e uma composição farmacêutica compreendendo um derivado de 4-azaindol como um ingrediente ativo.
BR112016007016A 2013-10-01 2014-09-30 composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica BR112016007016A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317363.8A GB201317363D0 (en) 2013-10-01 2013-10-01 Novel compounds
PCT/IB2014/001978 WO2015049574A1 (en) 2013-10-01 2014-09-30 4-azaindole derivatives

Publications (2)

Publication Number Publication Date
BR112016007016A2 BR112016007016A2 (pt) 2017-08-01
BR112016007016A8 true BR112016007016A8 (pt) 2020-02-27

Family

ID=49585123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007016A BR112016007016A8 (pt) 2013-10-01 2014-09-30 composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica

Country Status (21)

Country Link
US (3) US20150094328A1 (pt)
EP (2) EP3052496B1 (pt)
JP (3) JP6517790B2 (pt)
KR (1) KR102248559B1 (pt)
CN (1) CN105873927B (pt)
AR (1) AR097866A1 (pt)
AU (1) AU2014330880B2 (pt)
BR (1) BR112016007016A8 (pt)
CA (1) CA2924619C (pt)
CL (1) CL2016000726A1 (pt)
ES (2) ES2710190T3 (pt)
GB (1) GB201317363D0 (pt)
HK (1) HK1223090A1 (pt)
IL (1) IL244609B (pt)
MX (1) MX368956B (pt)
PE (1) PE20160839A1 (pt)
PH (1) PH12016500529A1 (pt)
RU (1) RU2688938C2 (pt)
SG (1) SG11201602052YA (pt)
TW (1) TW201546070A (pt)
WO (1) WO2015049574A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有maba化合物和皮質類固醇之組合
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
PT3134386T (pt) 2014-04-23 2020-08-25 Takeda Pharmaceuticals Co Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物
DK3303331T3 (en) * 2015-06-08 2019-04-23 Suven Life Sciences Ltd MUSCARIN M1 RECEPTOR-POSITIVE ALLOSTER MODULATORS
SI3347349T1 (sl) * 2015-09-10 2019-12-31 Suven Life Sciences Limited Derivati fluoroindola kot muskarinski M1 receptor pozitivni alosterni modulatorji
KR20180110132A (ko) * 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CA3076757C (en) * 2017-10-18 2022-10-11 Suven Life Sciences Limited Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
AU2018354969B2 (en) * 2017-10-27 2020-09-17 Suven Life Sciences Limited Polycyclic amides as muscarinic M1 receptor positive allosteric modulators
US12065433B2 (en) 2018-10-24 2024-08-20 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물
CN118440041B (zh) * 2024-07-02 2024-09-27 苏州凯瑞医药科技有限公司 一种手性4-氨基-3-羟基四氢吡喃的制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003044018A1 (en) 2001-11-19 2003-05-30 Neurogen Corporation 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
JP2006522746A (ja) 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 置換されたアミドの薬学的使用
EP1615667A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S Combinations of an 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス,インコーポレーテッド 5−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
CA2691512A1 (en) 2007-08-10 2009-02-19 H. Lundbeck A/S Heteroaryl amide analogues
ATE541845T1 (de) 2007-08-29 2012-02-15 Schering Corp 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
EP2244577B1 (en) * 2008-01-25 2012-10-31 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
MX2010007661A (es) 2008-01-31 2010-08-03 Sanofi Aventis Azaindol-3-carboxamidas ciclicas, su preparacion y su uso como productos farmaceuticos.
US20110098483A1 (en) 2008-03-27 2011-04-28 University Of Southern California Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof
WO2009121623A2 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
AU2009283195A1 (en) 2008-08-18 2010-02-25 Yale University MIF modulators
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
MY162502A (en) 2008-11-20 2017-06-15 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
WO2010063634A1 (en) 2008-12-05 2010-06-10 F. Hoffmann-La Roche Ag Pyrrolopyrazinyl urea kinase inhibitors
CN102325752B (zh) 2008-12-19 2015-02-04 百时美施贵宝公司 咔唑和咔啉激酶抑制剂
EP2398324B1 (en) 2009-02-23 2014-09-03 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
US8816085B2 (en) * 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
AU2010286683B9 (en) 2009-08-31 2014-09-04 Merck Sharp & Dohme Llc Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
NZ600674A (en) * 2009-12-17 2013-05-31 Merck Sharp & Dohme Quinoline amide m1 receptor positive allosteric modulators
US8383638B2 (en) 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
JP2013515725A (ja) 2009-12-23 2013-05-09 サノフイ [4[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−(1h−ピロロ−ピリジン−イル)−メタノン類及びその合成
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
WO2011159553A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
EP2582676B1 (en) 2010-06-15 2016-12-14 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EP2624697B1 (en) 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
EP2709451B1 (en) 2011-05-17 2015-12-30 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
EP2709621B1 (en) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
EP2709624B1 (en) 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
AU2012328476B2 (en) 2011-10-28 2017-03-30 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
WO2013091773A1 (en) 2011-12-22 2013-06-27 Merck Patent Gmbh Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US9012445B2 (en) * 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors
EA028611B1 (ru) * 2013-07-17 2017-12-29 Глоубал Элаенс Фор Тб Драг Дивелопмент Азаиндольные соединения, их получение и способы их применения
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
EP3049391B1 (en) * 2013-09-27 2018-12-26 F.Hoffmann-La Roche Ag Indole and indazole derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
US10072005B2 (en) 2018-09-11
AU2014330880B2 (en) 2019-01-31
RU2016116775A3 (pt) 2018-06-27
ES2807221T3 (es) 2021-02-22
JP2016531890A (ja) 2016-10-13
US20180208593A1 (en) 2018-07-26
CA2924619C (en) 2021-12-07
CN105873927A (zh) 2016-08-17
KR20160072133A (ko) 2016-06-22
JP6899944B2 (ja) 2021-07-07
US20150094328A1 (en) 2015-04-02
KR102248559B1 (ko) 2021-05-04
WO2015049574A1 (en) 2015-04-09
EP3052496B1 (en) 2018-11-28
CL2016000726A1 (es) 2016-09-23
MX368956B (es) 2019-10-23
JP2019112433A (ja) 2019-07-11
TW201546070A (zh) 2015-12-16
HK1223090A1 (zh) 2017-07-21
US9926312B2 (en) 2018-03-27
PH12016500529A1 (en) 2016-05-16
JP2020143100A (ja) 2020-09-10
RU2688938C2 (ru) 2019-05-23
AR097866A1 (es) 2016-04-20
IL244609B (en) 2019-12-31
CA2924619A1 (en) 2015-04-09
EP3489237B1 (en) 2020-05-13
ES2710190T3 (es) 2019-04-23
EP3489237A1 (en) 2019-05-29
SG11201602052YA (en) 2016-04-28
JP6517790B2 (ja) 2019-05-22
PE20160839A1 (es) 2016-08-20
GB201317363D0 (en) 2013-11-13
US20160244445A1 (en) 2016-08-25
IL244609A0 (en) 2016-04-21
EP3052496A1 (en) 2016-08-10
BR112016007016A2 (pt) 2017-08-01
MX2016004014A (es) 2016-09-21
RU2016116775A (ru) 2017-11-09
AU2014330880A1 (en) 2016-04-07
CN105873927B (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
BR112016007016A8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
ECSP16090152A (es) Compuesto heterocíclico que contiene nitrógeno
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112015018087A8 (pt) composto, composição farmacêutica e uso
PH12018501731A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
CL2008001560A1 (es) Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico.
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
BR112018001469A2 (pt) composto, composição farmacêutica e uso de um composto
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
CL2008002876A1 (es) Compuestos derivados de heterociclo sustituidos, moduladores de gamma-secretasa; composicion farmaceutica que los comprende; uso en el tratamiento de enfermedades neurodegenerativas como alzheimer o sindrome de down.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
CR20180368A (es) Compuestos de dihidroquinolinsulfonamida de alquilo
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CL2008001559A1 (es) Compuestos heterociclos que contienen al menos un atomo de nitrogeno, moduladores de gamma secretasa; composiciones farmaceuticas que los comprenden; uso de los compuestos en la preparacion de medicamentos para tratar trastornos del sistema nervioso central, tal como alzheimer; y kit que incluye a la composicion farmaceutica.
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time